Anakinra Prophylaxis for Recurrent Severe ICANS Associated With Tarlatamab in Small Cell Lung Cancer: Case Report
David W. Shia, Suwicha Limvorasak, Karen L. Reckamp, Kamya Sankar · 2026
Read Anakinra Prophylaxis for Recurrent Severe ICANS Associated With Tarlatamab in Small Cell Lung Cancer: Case Report by David W. Shia, Suwicha Limvorasak, Karen L. Reckamp, Kamya Sankar (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13499106.txt.
Description
David W. Shia and others report using anakinra to prevent recurrent severe brain toxicity from tarlatamab in small cell lung cancer. In 2026, the case concerns a patient with relapsed disease whose tarlatamab treatment was complicated by repeated severe immune effector cell-associated neurotoxicity syndrome. That syndrome is a rare but serious side effect of T-cell engaging therapy. Real-world experience managing this toxicity remains limited.
Later doses added prophylactic anakinra, an interleukin-1 dock blocker, which was well tolerated and allowed therapy to continue. The patient achieved a clear medical and radiographic response, including response inside the brain. The authors call for further study of interleukin-1 blockade as prevention for patients at higher risk of severe neurotoxicity.
Catalog record
| CREATOR | David W. Shia, Suwicha Limvorasak, Karen L. Reckamp, Kamya Sankar |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 15 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |